GlassScriptPhysician profile
Meredyth Blair Hall
NPI 1386118354
$1,098.04
in general payments reported to CMS, 2019-2025
12 companies · $72.24 in 2025
The $72.24 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $485 · 2023: $403 · 2024: $138 · 2025: $72.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $235.31 | 2022-2025 | Tremfya |
| Glaxosmithkline, LLC. | $224.00 | 2022-2024 | Benlysta |
| Abbvie INC. | $183.00 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $100.47 | 2022 | |
| Amgen INC. | $90.81 | 2022-2024 | Enbrel, Tavneos |
| Lilly USA, LLC | $59.65 | 2022-2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $52.82 | 2023 | Orencia |
| Pfizer INC. | $40.71 | 2022-2024 | |
| Ucb, INC. | $38.99 | 2023 | Cimzia |
| Novartis Pharmaceuticals Corporation | $29.99 | 2023 | |
| Organon LLC | $21.87 | 2022 | |
| Aurinia Pharma U.S., INC. | $20.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredyth Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.